View full meeting coverage »

Eyetube Meeting Coverage:

2018 Euretina Meeting



Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Three Exciting New Drugs

  Channels: Retina | Posted 9/22/2018

Pravin U. Dugel, MD, reviews recent clinical trial data concerning three new drugs: brolucizumab (formerly RTH258, Novartis), a humanized single-chain antibody fragment; faricimab (formerly RG7716, Genentech), the first bispecific antibody designed for intraocular use; and RGX-314 (REGENEXBIO), a one-time subretinal treatment for wet age-related macular degeneration.

AMD • brolucizumab (RTH258; Alcon/Novartis) • Subretinal Injection • Wet AMD

2 / 12 Series: 2018 Euretina Meeting